Effect of nitric oxide inhalation on respiratory system resistance in chronic obstructive pulmonary disease

N. Roger, J.A. Barberà, R. Farré, A. Cobos, J. Roca, R. Rodriguez-Roisin

ABSTRACT: Nitric oxide (NO) has been identified as a neurotransmitter of non-adrenergic noncholinergic bronchodilator nerves. To investigate whether inhaled NO exerts a bronchodilator effect in patients with chronic obstructive pulmonary disease (COPD), we measured the resistance of the respiratory system, using the forced oscillation technique, while breathing NO.

Eight patients with COPD (7 men and 1 woman; aged 66±7 yrs (mean±SD); forced expiratory volume in one second (FEV1) 37±17% of predicted) and eight healthy subjects (7 men and 1 woman; 33±4 yrs; FEV1 108±14% pred) were studied. Nitric oxide, at a concentration of 40 parts per million (ppm) in air, was inhaled for 20 min. Total resistance (Rrs) and reactance (Xrs) of the respiratory system, arterial oxygen saturation, heart rate, tidal volume, and breathing frequency were continuously recorded at baseline, and during and after ceasing NO inhalation. Methaemoglobin levels were additionally measured in healthy subjects.

At baseline, patients with COPD showed higher Rrs than healthy subjects (Rrs at 10 Hz (Rrs,10) 4.97±2.19 vs 2.29±0.65 hPa·L⁻¹·s⁻¹), during NO inhalation, no significant change in Rrs or in Xrs was observed. Mean variation in Rrs,10 while breathing NO was negligible and similar in the two groups (-0.10±0.13 hPa·L⁻¹·s⁻¹ in COPD patients and -0.02±0.13 hPa·L⁻¹·s⁻¹ in healthy subjects). Moreover, there were no differences in oxygen saturation, heart rate, tidal volume and breathing frequency during NO inhalation. Methaemoglobinemia increased at the end of NO inhalation (from 0.48±0.18 to 0.81±0.16%), and this increment remained 10 min later (0.86±0.31%).

From these results, we conclude that inhaled nitric oxide, at a concentration of 40 ppm, exerts no effect on respiratory system resistance in patients with chronic obstructive pulmonary disease or in healthy subjects.

to investigate the effect of inhaled NO on the two components of respiratory system impedance, namely resistance ($R_{rs}$) and reactance ($X_{rs}$), that were measured simultaneously with NO inhalation by using the forced oscillation technique, in healthy subjects and patients with COPD.

**Methods**

**Subjects**

The study was conducted in two groups of subjects: 1) eight patients with COPD with moderate to severe airflow obstruction (forced expiratory volume in one second (FEV1) 37±17% predicted, mean±SD); and 2) eight healthy volunteers with normal lung function (FEV1 108±14% pred). Main anthropometric and lung function data are shown in table 1. Patients with COPD were studied under stable clinical conditions. Inhaled short-acting bronchodilators and long-acting theophyllines were withdrawn 8 and 24 h before the study, respectively. The study was approved by the Research Committee on Human Investigations of Hospital Clínic and informed consent was obtained from each participant after the purpose of the study had been explained and understood.

**Procedures**

Forced spirometry before and after use of bronchodilator (300 µg of salbutamol) was performed the day before the study using a water-sealed spirometer (Biomedin, Milan, Italy). All but two COPD patients showed no significant bronchodilation with salbutamol. Mean values of forced spirometry and bronchodilator response are shown in table 1. Predicted values are those of our own laboratory [12].

Nitric oxide was delivered by means of a nonrebreathing circuit (fig. 1). Subjects breathed through a four-side ports valve. The inspiratory port was connected by a unidirectional valve ("V" valve; W.E. Collins, Braintree, MA, USA) to a 30 L reservoir (W.E. Collins, Braintree, MA, USA). A manually-operated three-way valve (WE Collins, Braintree, MA, USA) made it possible to connect the subject either to the NO breathing circuit or to room air. The inspired gas was a mixture of O2, N2 and NO, obtained using a set of calibrated rotameters (Tecfluid SA, Barcelona, Spain). NO was obtained from a stock tank containing a mixture of 800 parts per million (ppm) of NO in N2 (Abelló, Barcelona, Spain). The estimated contact time of NO with O2 using this setting was approximately 3 min. Inspired concentrations of NO and nitrogen dioxide (NO2) were continuously monitored using a chemiluminescence analyser (model CLD 700AL; Eco Physics, Dürnten, Switzerland) at the inspiratory port. The mean concentration of NO that was actually inhaled was 38.5±1.8 ppm, and that of NO2 was 1.3±0.4 ppm. Inspired O2 concentration was also continuously controlled using a zirconium analyser (CPX System; Medical Graphics Corp., St. Paul, MN, USA) and adjusted at 21%.

Total resistance and reactance of the respiratory system were measured using the forced oscillation technique, as described in detail previously [11, 13]. The forced oscillations (2 hPa peak-to-peak, 4–32 Hz) were generated by means of a loudspeaker enclosed in a chamber, servocontrolled [14] to withstand the pressure variation due to the subject's breathing, and applied at the mouth of the subject through the four-port valve (fig. 1). During the measurement, the subject wore a noseclip and supported her/his cheeks whilst breathing spontaneously. Flow at the mouth was measured with a mesh-wire screen pneumotachograph (0.54 hPa·L⁻¹) and an attached pressure transducer (±2 hPa, model LCVR; Celeasco, Canoga Park, CA, USA). Pressure at the mouth was sensed with a piezoresistive transducer (model 174; Honeywell). Pressure and flow signals were filtered, sampled and processed as described previously [15]. Forced oscillation data were described by the mean value both of resistance ($R_{rs}$) and reactance ($X_{rs}$) over the whole frequency band explored (6–30 Hz), and also by the resistance at

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>Healthy (n=8)</th>
<th>COPD (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>33±4</td>
<td>66±7</td>
<td></td>
</tr>
<tr>
<td>Gender M/F</td>
<td>7/1</td>
<td>7/1</td>
</tr>
<tr>
<td>FEV1 L</td>
<td>4.46±0.82</td>
<td>1.08±0.55</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>108±14</td>
<td>37±17</td>
</tr>
<tr>
<td>FVC % pred</td>
<td>100±13</td>
<td>60±17</td>
</tr>
<tr>
<td>BR % baseline</td>
<td>3±3</td>
<td>8±12</td>
</tr>
</tbody>
</table>

Values are presented as mean±SD. COPD: chronic obstructive pulmonary disease; M: male; F: female; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; % pred: percentage of predicted value; BR: bronchodilator response to 300 µg salbutamol as % change in FEV1.
oscillation frequency of 6–14 Hz ($R_{s,10}$). The latter parameter was used because in patients with COPD lung resistance shows a negative relationship with oscillation frequency [16].

Arterial oxygen saturation and heart rate were recorded using a pulse oximeter (Criticare CSI 504; Wankesha, WI, USA). Expiratory flow was continuously measured using a calibrated Fleisch pneumotachometer (E. Jaeger, Würzburg, Germany), and tidal volume was derived from the electrical integration of the flow signal and a differential pressure transducer (MP45±2 cmH2O; Validyne Corp., Northridge, CA, USA). Both haemoglobin and methaemoglobin were measured by light absorption using a CO-oximeter (Model 482; Instrumentation Laboratories, Milan, Italy) in blood samples collected through a polyethylene catheter inserted into a peripheral vein.

**Study protocol**

Initially, subjects breathed room air for 10 min. Subsequently, they were connected to the NO delivery system and breathed NO at a concentration of 40 ppm in air over a period of 20 min. After this, the inspiratory circuit was switched to room air again for an additional 10 min. During the study, $R_s$ and $X_s$ were measured by forced oscillation at 1–3 min intervals. Overall, more than 25 measurements were performed in each subject. Arterial oxygen saturation ($S_aO_2$), heart rate, tidal volume and breathing frequency were continuously recorded. Inspired NO, NO2 and O2 concentrations were also continuously monitored. In healthy volunteers, peripheral venous blood was sampled to measure methaemoglobin concentration at baseline, at the end of the NO breathing period, and 10 min after stopping it.

**Statistical analysis**

Data are expressed as mean±sd. To assess the effect of NO inhalation on the different variables, individual plots of each variable against time were visually inspected. Since no specific pattern of change was observed, we averaged individual data at baseline, during NO inhalation, and after inhalation [17], and compared them using paired t-tests. Because measurements at baseline in patients with COPD clearly differed from those of healthy subjects (unpaired t-test), the difference between baseline and NO inhalation was considered the most appropriate variable to assess the effect of NO on the two populations, comparisons being performed by unpaired t-tests.

To further analyse the effect of NO on $R_{s,10}$, the major end-point variable, a linear regression model of the $R_{s,10}$ values during NO inhalation as a function of the baseline values and group was fitted. The 95% confidence interval of the regression coefficient was computed and used to assess the sensitivity of the test in detecting changes of $R_{s,10}$ during NO inhalation.

**Results**

At baseline, patients with COPD showed higher values of $R_{s,10}$, $R_s$ and breathing frequency, and lower $X_s$, $S_aO_2$ and $X_s,10$, than healthy subjects (table 2).

No specific pattern of response was shown in the individual time courses of $R_{s,10}$ throughout the study (fig. 2). Furthermore, no significant differences were shown between the average values at baseline, during NO inhalation, and thereafter (table 2). Mean change in $R_{s,10}$ between baseline and NO inhalation in patients with COPD was -0.10±0.36 hPa·L⁻¹·s (-3.0±9.0% from baseline), and in healthy subjects was -0.02±0.13 hPa·L⁻¹·s (-1.4±5.6% from baseline). No difference in such change was shown between the two groups (p=0.54). Furthermore, the fitted linear model of the relationship between $R_{s,10}$ values at baseline with those observed during NO inhalation failed to detect any group effect. After removing this effect, the estimated regression parameter of this relationship was 1.02, indicating no practical variation from the identity (fig. 3).

Values of $R_s$ were analogous to those of $R_{s,10}$, and no differences were observed among the measurements performed in each condition (table 2). Furthermore, mean change in $R_s$ during NO inhalation was similar in the two groups (-0.07±0.28 and 0.01±0.14 hPa·L⁻¹·s, in COPD patients and healthy subjects, respectively; p=0.67). The evolution of $X_s$ was similar to that of $R_s$. At baseline, patients with COPD showed lower values of $X_s$ than healthy subjects (table 2). Individual time courses of $X_s$ throughout the study showed no specific change. Moreover,

<table>
<thead>
<tr>
<th>Table 2. – Lung mechanics, cardiac and ventilatory responses to nitric oxide inhalation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Healthy subjects</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
</tr>
<tr>
<td>$R_{s,10}$ hPa·L⁻¹·s</td>
</tr>
<tr>
<td>$R_s$ hPa·L⁻¹·s</td>
</tr>
<tr>
<td>$X_s$ hPa·L⁻¹·s</td>
</tr>
<tr>
<td>$S_aO_2$ %</td>
</tr>
<tr>
<td>HR beats·min⁻¹</td>
</tr>
<tr>
<td>$V_t$ mL</td>
</tr>
<tr>
<td>$f_t$ breaths·min⁻¹</td>
</tr>
</tbody>
</table>

Values are the average of continuously recorded measurements in each period. COPD: chronic obstructive pulmonary disease; $R_{s,10}$: total respiratory resistance at 10 Hz; $R_s$: mean value of total respiratory resistance; $X_s$: mean value of total respiratory reactance; $S_aO_2$: arterial oxygen saturation; HR: heart rate; $V_t$: tidal volume; $f_t$: breathing frequency. *: p<0.05 compared with healthy subjects.
no significant difference was observed between average values at baseline, during NO inhalation, and thereafter (table 2). Mean change in $R_{rs}$ during NO inhalation was $0.09\pm0.27$ hPa·L$^{-1}$·s in patients with COPD, and $0.11\pm0.12$ hPa·L$^{-1}$·s in healthy subjects, such a difference being similar in the two groups ($p=0.88$).

Furthermore, no changes were found in $S_aO_2$, heart rate, breathing frequency and tidal volume whilst breathing NO (table 2). Methaemoglobin levels measured in healthy subjects increased at the end of NO inhalation (from $0.48\pm0.18$ to $0.81\pm0.16\%$; $p<0.01$), and this increment persisted 10 min later ($0.86\pm0.31\%$; $p<0.05$).

**Discussion**

The present study shows that the inhalation of NO, at a concentration of 40 ppm, has no effect on the resistance and reactance of the respiratory system in patients with COPD or in healthy subjects.

Our results are consistent with those of HÖGMAN and co-workers [7], who found no significant changes in specific airway conductance ($sGaw$), measured by body plethysmography after breathing NO at a concentration of 80 ppm for 10 min, either in healthy subjects or in patients with COPD. By contrast, they found a weak but significant bronchodilator effect of NO in patients with bronchial asthma and in subjects with bronchial hyperreactivity after methacholine challenge [7]. In the asthmatics, $sGaw$ increased from $0.4\pm0.1$ to $0.6\pm0.2$ s$^{-1}$·kPa$^{-1}$ after 80 ppm NO inhalation. However, this change was much lower than that induced by a $\beta_2$-agonist inhalation. In the patients with bronchial hyperreactivity, there was a 45$\pm$16% decrease in the $sGaw$ response to methacholine when the nebulization was performed simultaneously with 80 ppm NO [7]. The rationale behind the bronchodilator effect of NO is based on its action as a neurotransmitter of NANC bronchodilatory nerves [4]. However, according to the results of the present study and those of HÖGMAN and co-workers [7], NO appears to exert no effect on bronchial tone in patients with fixed airflow obstruction, at concentrations both of 40 and 80 ppm. This is not surprising, since airflow obstruction in COPD is mostly produced by structural abnormalities of the airways and lung parenchyma, whilst the neural regulation of bronchial tone plays only a minor role [18].

It might be speculated that the potential bronchodilator effect of NO could have been neutralized by a bronchoconstrictor action of NO$_2$, that was generated from the mixing of NO with O$\_2$. We think this was unlikely, since the inhalation of NO$_2$ during short periods of time at concentrations up to 4 ppm exerts no significant effect on lung function either in healthy subjects or in COPD patients [19].

The rate of disappearance of NO in exhaled air, after breathing it for a short period of time is very high [20]. GERLACH et al. [21] reported that the vascular effects of NO reversed 1 min after interruption of its inhalation, at doses in the parts per billion (ppb) range. By contrast, FROSTELL et al. [20] found the vasodilator effect of NO persisted 6 min after discontinuing its inhalation, at a
concentration of 40 ppm. Since the time course of the potential bronchodilator effect of NO is unknown, our study was specifically designed to test $R_s$ and $X_s$ during and not after NO inhalation by using the forced oscillation technique. This technique has the advantage that it can be applied during normal breathing of room air or other gases, and does not require co-operation from the subject to perform panting or special ventilatory manoeuvres, such as deep inspirations. No changes in $R_s$ or $X_s$ were identified throughout the study period, either in healthy subjects or in COPD patients (fig. 2). Accordingly, our results indicate that the lack of effect of NO on airway tone cannot be attributed to its wash-out from the airways.

It could be argued that the forced oscillation technique is not sensitive enough to detect moderate changes in airway resistance. We discard this possibility because, as has been recently reported, forced oscillation is among the most sensitive tests to detect reversibility of airway obstruction. Van Noord and co-workers [22] have shown that the inhalation of a small dose of salbutamol (40 µg) induced a 21±17% decrease in $R_s$ measured by forced oscillation in patients with moderate airflow obstruction (FEV1 57±24% pred). The percentage change in $R_s$ was lower than that of $sGaw$ (72±72%) but slightly greater than that of FEV1 (19±16%). Furthermore, the same group of investigators [23], as well as Duverman et al. [24], have shown that measurements of $R_s$ at oscillation frequencies similar to those reported in the present study are among the most reliable and discriminative parameters to be used for the assessment of bronchial reactivity to histamine challenge. In our laboratory, we have previously reported significant changes in $R_s$, measured by forced oscillation, following methacholine challenge in patients with mild bronchial asthma [25], and also after platelet-activating factor (PAF) inhalation both in healthy subjects [26] and patients with asthma [27]. Moreover, in our study the 95% confidence interval of the relationship between values of $R_s$,10 at baseline with those observed during NO inhalation ranged 0.91–1.14 (fig. 3), indicating that the uncertainty about the potential change in $R_s$,10 during NO inhalation was confined to a -10% decrease up to a +14% increase.

In our study, patients with COPD exhibited a greater intra-individual variability than healthy subjects (fig. 2). Nevertheless, the potential effect of such variability on the results was minimized by the multiple measurements that were performed in each subject breathing either room air or NO. The mean coefficient of variation of $R_s$,10 at baseline was 5.7±2.8% in healthy subjects and 10.7±7.4% in patients with COPD, values lower than those reported by Van Noord and co-workers [22] both for $sGaw$ (14.9%) and $R_s$ (15.2%) in patients with airflow obstruction.

The effects of inhaled NO on pulmonary circulation and gas exchange in humans have been reported using a wide range of concentrations, 0.06–80 ppm [1–3, 18, 19]. The 40 ppm concentration used in the present study was chosen because at this dose inhaled NO might improve gas exchange in COPD [2]. Our results indicate that at this concentration NO has no bronchodilator effect of clinical relevance. Therefore, despite the fact that inhaled NO can ameliorate pulmonary hypertension in COPD patients [2, 3], our results support the notion that the potential benefit of inhaled NO on gas exchange in these patients, if any, is likely to be related to a selective vasodilation of well-ventilated alveolar units [1], rather than to an increase of ventilation in alveolar units with low $V_{A}/Q$ ratio, as suggested previously [3]. Although the effects of NO on gas exchange were not specifically addressed in our present study, no changes were observed in arterial oxygen saturation measured by pulse oximetry. The latter, however, has a low sensitivity to detect minor changes in arterial oxygen tension ($P_{a,O_2}$) [28].

The increase in methaemoglobin during and after NO inhalation indicates that NO had a good access to the alveolar space and that the inhaled dose of NO was sufficient to bind to haemoglobin to a significant level, even in the absence of an effect on airway resistance.

In summary, our study supports the view that inhaled NO, at a concentration of 40 ppm, exerts no significant effect on respiratory system resistance and reactance in patients with COPD or in healthy subjects.

Acknowledgements: The authors thank the technical staff of the Pulmonary Function Laboratory for their cooperation, J. Cardús for his excellent assistance, and J. Milic-Emili for helpful comments.

References


14. Farré R, Ferrer M, Rotger M, Navajas D. Servocontrolled generator to measure respiratory impedance from 0.25 to 26 Hz in ventilated patients at different PEEP levels. *Eur Respir J* 1995; 8: 1222–1227.


